Community curated by people like you

Vaccines and Immunization Policy stories

Sep 8, 2026

FDA Approves First mRNA Flu Vaccine for Adults 50 and Older

Moderna's mFLUSIVA becomes the first mRNA-based seasonal influenza vaccine to receive FDA approval.

Sep 8, 2026·4 sources

00

Top claims

▪mRNA flu vaccines will prove more effective than traditional flu shots at preventing seasonal influenza
▪FDA approved Moderna's mFLUSIVA on August 5, 2026, the first mRNA-based seasonal influenza vaccine
▪The vaccine is approved for adults 50 and older, the age group that accounts for most flu deaths

Subtopics

Drug Approval and Clinical Trials1 mRNA Flu Vaccine Approval 20261 Vaccine development and innovation1

Related timelines

Payments

Trump administration

Congress

Iran War

Russia-Ukraine war